POS1484 SELF-ESTEEM AS A DETERMINANT OF SEXUAL FUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS

Background Patients with rheumatic diseases, particularly systemic lupus erythematosus (SLE), present greater sexual dysfunction (SxD) than patients other chronic diseases. SxD is multifactorial and may be linked to both disease-related psychological factors, as well hormonal imbalance drug treatment. Self-image self-esteem, which have not been thoroughly studied in SLE patients, related interest thereby also affect function. Objectives We addressed the association between body global self-worth functioning patients. Methods performed a transversal study tertiary care center Mexico City. ≥18 years old who fulfilled EULAR/ACR criteria for were included. Body self-esteem was assessed by Self-esteem Scale (BSES) Rosenberg´s Self-Esteem (RSES). Sexual function evaluated CSFQ-14 questionnaire. Disease activity damage SLEDAI SLICC scores, respectively. Relevant demographic, clinical serological characteristics recorded. used univariate multivariate analysis determine variables. Statistical using SPSS (V.25). Results included total of 343 whom analyzed. 280 since 62 did complete Most female (87%), mean age 41 (±12) BMI 25.65 kg/m 2 (±4.9). The scores 2.45 (±2.72) 0.8 points (±1.04), score RSES 32.09 (± 5.84) females 33.57 4.97) males. BSES 189.5 (±47.3) 207.1 (±36.6) There no these prednisone dosage, BMI, or scores. found that associated lower ( p<0.0001 ) ), according their respective (see Table 1). Also, correlation questionnaires (BSES RSES) found. Interestingly, higher male population (r=0.45, p=0.008 r=0.47 p= 0.006 RSES, respectively) women (r=0.25, p=0.0001 r=0.18 p=0.004 showed p=0.003 , 0.96 [0.94-0.98 95% CI]) p=0.013 1.080 [1-1.14 independent risk factors SxD. observed trend (p=0.055, 1.007 [1-1.15 factor. Other variables, such prednisone, major depressive disorder show an Conclusion To our knowledge, this first demonstrate reliable Considering high impact on quality life, findings reinforce importance routinely acknowledging biopsychosocial aspects (and only ones) medical Reference [1]Tristano, A.G. diseases Rheumatol Int 29, 853–860 (2009). 1. Differences without Variables Mean ± SD No Comparison p value) (kg/m 25.2 4.6 26.1 5.5 0.16 (points) 2.4 2.7 2.3 2.5 0.71 SLICC-DI 1.0 0.6 0.9 0.09 C3 levels (mg/dL) 111.6 30.3 117.1 32.8 0.19 C4 22.1 10.3 20.7 10.9 0.34 anti-dsDNA antibodies (IU/mL) 151.1 732.4 36.1 63.5 Prednisone dose (mg) 8.7 3.8 6.1 0.42 Attractive 37.2 13.8 46.8 8.6 <0.0001 Satisfaction 151.2 35.7 162.7 29.1 <0.006 188.4 44.9 207.9 40.1 31.6 ±5.0 34.4±6.4 *Values shown bold represent statistically significant values. Acknowledgements: NIL. Disclosure Interests Daniela Marengo-Rodríguez: None declared, Monserrat Ibarra-Velasco Siles: Ana Barrera-Vargas Speakers bureau: Sanofi, Javier Merayo-Chalico Pfizer, Janssen.